Sorafenib: a clinical and pharmacologic review

Bibliography

• Wilhelm S, Carter C, Lynch M, Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44, Erratum in: Nat Rev Drug Discov 2007;6:126
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW, The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9
   PubMed Web of Science ®Google Scholar
• Himmelsbach K, Sauter D, Baumert TF, New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009;58:1644-53
   PubMed Web of Science ®Google Scholar
• Molhoek KR, McSkimming CC, Olson WC, Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009;58:867-76
   PubMedGoogle Scholar
• Strumberg D, Richly H, Hilger RA, Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacology and Biopharmaceutics NDA Review for Sorafenib Tosylate (NDA 21 923), F.C.F.D.E.A. RESEARCH, Editor, 2005
   Google Scholar
• BAY 43-9006 (sorafenib) Investigator's Brochure. Bayer Healthcare AG, Version 10.0, July 1, 2009
   Google Scholar
• Richly H, Kupsch P, Passage K, Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 2004;42:650-1
   PubMedGoogle Scholar
• Richly H, Henning BF, Kupsch P, Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
   PubMed Web of Science ®Google Scholar
• Adjei AA, Molina JR, Mandrekar SJ, Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13:2684-91
   PubMed Web of Science ®Google Scholar
• Mross K, Steinbild S, Baas F, Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 2007;43:55-63
   PubMed Web of Science ®Google Scholar
• Duran I, Hotte SJ, Hirte H, Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:4849-57
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14:4836-42
   PubMed Web of Science ®Google Scholar
• Moretti LV, Montalvo RO. Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin. Am J Health Syst Pharm 2009;66:2123-5
   PubMed Web of Science ®Google Scholar
• Widemann BC, Fox E, Adamson PC, Phase I study of sorafenib in children with refractory solid tumors: a Children's Oncology Group Phase I Consortium trial (abstract 10012). J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009;27:1800-5
   PubMed Web of Science ®Google Scholar
• Rey PM, Villavicencio H. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 2008;74:245-6
   PubMed Web of Science ®Google Scholar
• Hilger RA, Richly H, Grubert M, Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 2009;47:61-4
   PubMedGoogle Scholar
• Blanchet B, Billemont B, Barete S, Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 2010;9:275-87
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, ; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• FDA. Center for drug evaluation and research approval package for: application number NDA 21-923-Pharmacology Review, 2005. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda_docs/nda/2005/021923_s000_Nexavar_BioPharmR.pdf
   Google Scholar
• Escudier B, Eisen T, Stadler WM, ; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34, Erratum in N Engl J Med 2007;357:203
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-18
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12
   PubMed Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6:569-79
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, ; panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
   PubMed Web of Science ®Google Scholar
• Escudier B. Sorafenib [corrected] in kidney cancer. Ann Oncol 2007;18(Suppl 9):90-3
   Google Scholar
• Bukowski R, Cella D, Gondek K, Escudier B; Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30:220-7
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE, Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-9
   PubMed Web of Science ®Google Scholar
• Himmelsbach K, Sauter D, Baumert TF, New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009;58:1644-53
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Fischer P, Inhibition of T-cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 1998;160:2579-89
   PubMed Web of Science ®Google Scholar
• Hipp MM, Hilf N, Walter S, Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20
   PubMed Web of Science ®Google Scholar
• Alfaro C, Suarez N, Gonzalez A, Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;100:1111-19
   PubMed Web of Science ®Google Scholar
• Hoechst B, Ormandy LA, Ballmaier M, A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008;135:234-43
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006;16:53-65
   PubMed Web of Science ®Google Scholar
• Ko HJ, Kim YJ, Kim YS, A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007;67:7477-86
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Ma G, Kao J, The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514-22
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-28
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010;28:1054-60
   PubMed Web of Science ®Google Scholar
• Newell P, Villanueva A, Friedman SL, Experimental models of hepatocellular carcinoma. J Hepatol 2008;48:858-79
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Johnson P, Knox J, Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) [abstract 128]. ASCO 2008 Gastrointestinal Cancers Symposium; January 2008; Orlando, FL, USA
   Google Scholar
• Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 2009;115:4646
   PubMedGoogle Scholar
• Bianchi G, Loibl S, Zamagni C, Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Gatzemeier U, Fossella F, Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-80
   PubMed Web of Science ®Google Scholar
• Maki RG, D'Adamo DR, Keohan ML, Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-40
   PubMed Web of Science ®Google Scholar
• Egberts F, Kahler KC, Livingstone E, Hauschild A. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 2008;31:398-403
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323-30
   PubMedGoogle Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Massard C, Zonierek J, Gross-Goupil M, Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010;21(5):1027-31
   PubMedGoogle Scholar